Chemoradiation of hepatic malignancies: Prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization

Ryan Hickey, Mary F. Mulcahy, Robert J. Lewandowski, Vanessa L. Gates, Michael Vouche, Ali Habib, Sheetal Kircher, Steven Newman, Halla Nimeiri, Al B. Benson, Riad Salem

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Purpose Radiosensitizing chemotherapy improves the outcomes in comparison with radiation alone for gastrointestinal cancers. The delivery of radiation therapy with yttrium90 (90Y) radioembolization, in combination with the radiosensitizing chemotherapeutic agent capecitabine, provides the opportunity to enhance the effects of radiation on hepatic malignancies. This phase 1 study sought to determine the maximum tolerated dose (MTD) of 90Y plus capecitabine in patients with cholangiocarcinoma or liver metastases confined to the liver. Methods and Materials Patients were given initial treatment at full-dose capecitabine during days 1 to 14 of a 21-day cycle. At days 1 to 7 of the second cycle, whole-liver 90Y was given at the test dose, after which time capecitabine was continued. Dose-limiting toxicity (DLT) was determined 6 weeks after 90Y infusion. If a DLT was not observed, the 90Y dose was escalated. The planned dose cohorts were 110, 130, 150, and 170 Gy. The primary endpoint was to determine the MTD of 90Y with full-dose capecitabine. Results Sixteen patients were treated according to the study protocol. Two patients experienced DLTs. Nine patients required capecitabine dose reduction as a result of toxicities attributable to capecitabine alone. The criteria for establishing 90Y MTD were not met, indicating an MTD of >170 Gy. Conclusion The MTD of 90Y delivered in conjunction with capecitabine in the setting of intrahepatic cholangiocarcinoma or metastatic disease confined to the liver exceeds 170 Gy. This is the highest 90Y dose reported to date and has important implications on combined therapy with the radiosensitizing oral chemotherapeutic capecitabine. Further studies are under way.

Original languageEnglish (US)
Pages (from-to)1025-1031
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume88
Issue number5
DOIs
StatePublished - Apr 1 2014

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Chemoradiation of hepatic malignancies: Prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization'. Together they form a unique fingerprint.

  • Cite this

    Hickey, R., Mulcahy, M. F., Lewandowski, R. J., Gates, V. L., Vouche, M., Habib, A., Kircher, S., Newman, S., Nimeiri, H., Benson, A. B., & Salem, R. (2014). Chemoradiation of hepatic malignancies: Prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. International Journal of Radiation Oncology Biology Physics, 88(5), 1025-1031. https://doi.org/10.1016/j.ijrobp.2013.12.040